A Real-world Study on the Influencing Factors of the Efficacy of Ruxolitinib Cream in the Treatment of Vitiligo
Vitiligo is a common chronic autoimmune skin disease that can occur on any part of the body and severely impacts patients' quality of life. Current treatment for vitiligo primarily include topical medications, phototherapy, systemic therapy and surgical interventions, but their efficacy is limited, often failing to achieve ideal therapeutic outcomes, and are associated with a high recurrence rate. This study is an investigator-initiated real-world research on the application of ruxolitinib cream for vitiligo treatment, with the primary objective of exploring the factors influencing the efficacy of ruxolitinib cream in treating vitiligo.
• Age12 years or older, any gender;
• SignedInformed Consent Form;
• Clinically diagnosed with non-segmental vitiligo;
• Vitiligo area less than 10% of body surface area;
• Agreed to discontinue all other vitiligo-related treatments from the screening visit until the final follow-up visit;
• Female subjects must not plan for pregnancy or oocyte donation from screening until 4 weeks after the last dose and must voluntarily adopt highly effective physical contraception; male subjects must not plan for fertility or sperm donation during the same period and must voluntarily adopt highly effective physical contraception. Methods include:
‣ Barrier methods: Condom or barrier cap (diaphragm or cervical cap);
⁃ Intrauterine device (IUD) or intrauterine system (IUS);
⁃ Surgical sterilization (bilateral oophorectomy with/without hysterectomy, total hysterectomy, bilateral tubal ligation, or vasectomy) performed ≥6 months prior to the first dose in the subject or their partner;
⁃ Other investigator-confirmed highly effective physical contraception.